Each one may require different treatments and have different safety considerations

Pharma pays $25M up front to use target discovery platform as privately-held Cerevance plots path forward for wholly-owned clinical program

Crenezumab, gantenerumab and solanezumab have all failed to delay Alzheimer’s onset in their first prevention trials; five more under way

Two and half decades after it was founded, Acumen goes public with revived amyloid therapy

The last three years of deals prioritize new modalities against known targets and CNS entry over discovery of new targets

Denali opens up about its technology for shuttling large molecules into the brain

Lilly’s solanezumab, Roche’s gantenerumab miss DIAN-TU endpoint in presymptomatic AD patients